来宝网 2012/5/14点击2672次
Facilities expansion will help serve the growing global demand for blood and cellular therapy products
LAKEWOOD, Colo.—May 10, 2012—Terumo BCT announced plans to invest in its existing U.S. manufacturing operations at its global headquarters, based in Lakewood, Colo., and to build a new manufacturing facility in Vietnam. Investment in the Colorado and Vietnam facilities will support growth and demand for blood and cellular therapy products and equipment globally.
Key Facts:
-
Terumo BCT's parent company, Terumo Corporation, is committing $100M to fund both projects
-
$6M is being leveraged to expand operations at the Colorado manufacturing facility
-
Investment in the Colorado facility is planned for FY2013
-
$94M is being invested in the new Vietnam facility
-
Ground breaking on the new Vietnam facility is expected to begin in early 2013 with plans to have the facility complete and operational by 2015
-
The Vietnam facility is being developed on an area of 10 hectares
-
Terumo BCT products are manufactured in five locations: China, India, Japan, Northern Ireland and the U.S.
-
Terumo BCT was established through the integration of CaridianBCT and Terumo Transfusion, following Terumo Corporation's acquisition of CaridianBCT in April 2011
-
Terumo BCT, headquartered in Lakewood, Colorado, is the only Terumo Corporation subsidiary with its global headquarters located outside of Japan
-
Terumo BCT has more than 2,600 associates, and customers in more than 120 countries and territories, with regional headquarters in Brussels, Buenos Aires, Hong Kong and Tokyo
-
Terumo BCT serves three primary customer segments: Blood Centers, Hospitals & Therapeutic Apheresis Centers and Biotech & Cell Processing
Key Quotes:
Koji Nakao, Terumo Corporation, Chairman and Representative Director
"The investment in these facilities demonstrates our commitment to investing in Terumo BCT and to contributing to the long-term goals of the business and our mission, at Terumo, of ‘Contributing to Society through Healthcare.'"
David Perez, Terumo BCT President and CEO; Terumo Corporation, Chairman, Blood Management Business Division
"This is an exciting time for our organization. In just 12 months, we combined the businesses of CaridianBCT and Terumo Transfusion to emerge as Terumo BCT, one united global leader in blood component, therapeutic apheresis and cellular technologies."
"With Terumo's investment we are able to expand our global capabilities and footprint to be even more responsive to the demands of the marketplace. This investment demonstrates Terumo's commitment to the industry, to our organization, and to better serve our current and future customers."
Craig Rinehardt, Terumo BCT Senior Vice President, Global Operations
"The investment being made in Terumo BCT's state-of-the-art facilities aligns our global manufacturing strategies, supports incremental capacity needs and furthers our commitment to our business continuity infrastructure. We remain focused on building the right products at the right time, while maintaining the highest level of quality and standards."
Key Resources:
About Terumo BCT:
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
About Terumo Corporation:
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
Contact:
Laura Fusco
Global Corporate Communications
Phone: +1.303.205.2546
科罗拉多州莱克伍德--(美国商业资讯)--Terumo BCT宣布计划对位于其科罗拉多州莱克伍德全球总部现有的美国制造业务进行投资，并计划在越南建造一个新的制造工厂。对科罗拉多和越南工厂所做的投资将为该公司的业务增长以及全球对血液与细胞治疗产品和设备不断增长的需求提供支持。
主要事实：
- Terumo BCT母公司泰尔茂株式会社(Terumo Corporation)将为两个项目提供1亿美元的资助
- 600万美元将用于拓展科罗拉多制造工厂的业务
- 计划于2013会计年对科罗拉多工厂进行投资
- 9400万美元将投入到越南的新工厂
- 越南新工厂预计将于2013年初开始破土动工，并计划在2015年前完工并投入使用
- 越南工厂将在面积达10公顷的区域内建造
- Terumo BCT产品在五个地点制造，即中国、印度、日本、北爱尔兰和美国
- Terumo BCT是泰尔茂株式会社于2011年4月收购CaridianBCT之后，将CaridianBCT和Terumo Transfusion合并打造而成
- 总部位于科罗拉多州莱克伍德的Terumo BCT是泰尔茂株式会社旗下唯一一个全球总部位于日本境外的子公司
- Terumo BCT在120多个国家和地区拥有2,600多名合作人与客户，地区总部分别设在布鲁塞尔、布宜诺斯艾利斯、香港和东京
- Terumo BCT为三个主要客户部门提供服务，即血液中心、医院与治疗性采集中心以及生物技术与细胞处理
关键引言：
泰尔茂株式会社董事长兼代表董事Koji Nakao
"对这些工厂所做的投资彰显了我们立志对Terumo BCT进行投入以及为泰尔茂的长期业务目标和’通过医疗奉献社会’的使命贡献力量的承诺。"
Terumo BCT总裁兼首席执行官，同时兼任泰尔茂株式会社血液管理业务部董事长的David Perez
"对我们公司而言，这是一个激动人心的时刻。短短12个月时间内，我们就将CaridianBCT和Terumo Transfusion的业务整合起来，打造了Terumo BCT-一个血液成分、治疗性血浆分离置换法和细胞技术领域齐心协力的全球领导者。"
"得益于Terumo的投资，我们就能够拓展我们的全球能力与业务版图，进而更好地满足市场需求。这项投资凸显了泰尔茂对整个行业、我们公司以及更好地服务于新老客户的至高承诺。"
全球运营部高级副总裁Craig Rinehardt
"对Terumo BCT最先进的工厂所做的投资符合我们的全球制造战略，可为不断增长的产能需求提供支持，并能加深我们对业务连续性架构的承诺。我们会继续致力于在合适的时间打造合适的产品，同时保持最高水准的质量与标准。"
主要资源：
关于Terumo BCT：
Terumo BCT在血液成分、治疗性血浆分离置换法和细胞技术领域居全球领先地位，是唯一一家拥有血液分离置换采集、手动及自动全血处理和病原菌灭活独特组合的公司，此外，公司还在治疗性采集和细胞处理领域拥有领先技术。我们相信血液具有巨大潜能，能为患者提供比当今更多的治疗方法及更好的治疗效果。正是这一信念激励我们不断创新，并加强与客户间的紧密合作。
关于泰尔茂株式会社：
总部位于东京的泰尔茂株式会社(Terumo Corporation)是全球领先的医疗设备制造商之一，业务遍及160多个国家。该公司成立于1921年，致力于开发、制造和分销世界级医疗设备，包括应用于心胸外科、介入手术和输血医学的产品；该公司还生产广泛的应用于医院和医生办公室的注射器和皮下注射器针头产品。泰尔茂致力于为医疗保健市场提供重要的产品与服务以及响应医疗保健提供商和所服务人员的需求，从而为社会做贡献。泰尔茂株式会社的股票在东京证券交易所（No. 4543, Reuters代码<4543.T>，或Bloomberg 4543: JP）一部上市，并且是日本领先股票指数日经225(Nikkei 225)的成分股。
免责声明：本公告之原文版本乃官方授权版本。译文仅供方便了解之用，烦请参照原文，原文版本乃唯一具法律效力之版本。
联系方式：
Terumo BCT
Laura Fusco, +1-303-205-2546
全球企业公关部
press@terumobct.com
